In discussion with Dr. Alexander Spira, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Spira:
- PAPILLON - Amivantamab Plus Chemo in Advanced NSCLC with EGFR Exon 20 Insertions
- MARIPOSA - Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC
- MARIPOSA-2 - Amivantamab Plus Chemo (with or without Lazertinib) vs Chemo in EGFR-mutated Advanced NSCLC After Progression on Osimertinib
- LIBRETTO-431 - First-line Selpercatinib or Chemo and Pembrolizumab in RET Fusion-Positive Advanced NSCLC
#ESMO #PrecisionMedicine #LungCancer #2023 #cancer #oncology #oncbrothers
Website: www.oncbrothers.com/
Twitter: / oncbrothers
Contact us at info@oncbrothers.com